Addiction Health Services Research Conference (AHSR Virtual)
Oct 14-16, 2020
Jonathan Ozik, Marynia Kolak, Qinyun Lin, Harel Dahari, Basmattee Boodram, John Schneider, Eric Tatara, Nicholson Collier. Measuring social and spatial inequities in access to opioid use disorder treatment for reducing HIV and HCV transmissions.
The Digital International Liver Congress, 55th annual meeting of the European Association for the Study of the Liver (EASL)
August 27-29, 2020
Preeti Dubey, Stephanie Maya, Elham Shirvani-Dastgerdi, Hannah Shanes, Susan L. Uprichard, Andrew Berneshawi, Harel Dahari*, Alexander Ploss*. Mathematical modeling of early hepatitis D virus kinetics in transgenic-hNTCP mice.
Christopher Koh, Julian Hercun, Farial Rahman, Amy Wen-Chun Huang, Ben L. Da, Pallavi Surana, Devika Kapuria, Yaron Rotman, Anusha Vittal, Christy Ann Gilman, Gil Ben-Yakov, Walter Chunwei Lai, Harel Dahari, Jeffrey S. Glenn, and Theo Heller. A Phase 2 Study of Lonafarnib, Ritonavir and Peginterferon Lambda for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study.
Society for Prevention Research (SPR) annual meeting, Virtual Conference
July 21-23, 2020
Basmattee Boodram, Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Jonathan Ozik, Harel Dahari. Towards achieving WHO’s hepatitis C incidence reduction objective by 2030 among persons who inject drugs: Modeling reveals need for retreatment.
70th Annual Meeting of the American Association for the study of Liver Diseases
Boston, Ma, USA
November 8-12, 2019
Christopher Koh, Ben L. Da, Pallavi Surana, Amy Wen-Chun Huang, Devika Kapuria, Yaron Rotman, Anusha Vittal, Christy Ann Gilman, Gil Ben-Yakov, Walter Chun-wei Lai, Farial Rahman, Julian Hercun, Harel Dahari, Jeffrey S. Glenn, and Theo Heller. A Phase 2 Study of Lonafarnib, Ritonavir and Lambda Interferon for 24 weeks: Interim End-of-Treatment Results from the LIFT HDV Study. Hepatology 2019; accepted (Oral Late breaking).
Ohad Etzion, Sarah Duehren, Saeed Sadiq Hamid, Yoav Lurie, Edward Gane, Nimrah Bader, David Yardeni, Anat Nevo-Shor, SM Channa, Minaz Mawani, Om Parkash, Kyunghee Yang, Diane Longo, Susan L. Uprichard; Robert G. Gish, Scott J. Cotler; Jeffrey Glenn, David Apelian, Harel Dahari. Characterization of HDV, HBsAg and ALT kinetics under Peginterferon-Lambda Monotherapy: The Phase 2 LIMT Study. Hepatology 2019; accepted (Late breaking).
Swikriti Dasgupta, Michio Imamura, Takashi Nakahara, Masataka Tsuge, Alexander Churkin, David Yardeni, Ohad Etzion, Susan L. Uprichard, Danny Barash, Scott J. Cotler, Harel Dahari*, Kazuaki Chayama*. Modeling-based response-guided therapy under glecaprevir/pibrentasvir may optimize duration of therapy in patients with compensated cirrhosis. Hepatology 2019; Vol 70(Suppl1):931A.
Kevin Walsh, Marianne Martinello, Alexander Churkin, Sijia Lou, Tanya Applegate, Ohad Etzion, Susan L. Uprichard, Scott J. Cotler, Danny Barash, Gail Matthews, Harel Dahari. Modeling indicates 100% negative predictive value of achieving cure in subjects with recent HCV infection treated for 6 weeks with sofosbuvir and ribavirin: The DARE II Study. Hepatology 2019; Vol 70(Suppl1):969A-970A.
Elham Shirvani-Dastgerdi, Hannah Shanes, Andrew Berneshawi, Harel Dahari*, Alexander Ploss*.HDV RNA decline post inoculation in human NTCP transgenic mice is biphasic. Hepatology 2019; Vol 70(Suppl1):623A-624A. 70th Annual Meeting of the American Association for the study of Liver Diseases. Boston, Ma, USA, Nov 8-12, 2019
Preeti Dubey, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Harel Dahari*, Kazuaki Chayama*. Understanding early HBV kinetics during infection and treatment in primary human hepatocytes: a data-driven mathematical modeling approach. Hepatology 201; Vol 70(Suppl1):178A. (Oral talk)
Alexander Gutfraind, Eric Tatara, Nicholson T. Collier, Scott J. Cotler, Stephen Feinstone, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Simulation of HCV vaccine clinical trials reveals opportunities and challenges for candidate HCV vaccines. Hepatology 2019; Vol 70 (Suppl1):990A.
4th Workshop on viral dynamics
Paris, France
October 2019
Peter Kumberger, Karina Durso-Cain, Yannik Schälte, Theresa Fink, Harel Dahari, Jan Hasenauer, Susan L. Uprichard, Frederik Graw. Hepatitis C virus spread kinetics reveal varying contributions of transmission modes to infection dynamics. Abstract (Oral Talk)
26th International Symposium on HCV and related Viruses
Seoul, South Korea
October 5-8, 2019
Dahari H*, Etzion O*, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Uprichard SL, Sneh Arbib, Munteanu D, Braun M, Cotler SJ, Abufreha N, Mor O, Shlomai A. Modeling based response guided therapy with DAA shortens treatment duration in HCV treated patients. (Oral Talk)
Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Basmattee Boodram, Jonathan Ozik, Harel Dahari. Agent-based modeling of persons who inject drugs in metropolitan Chicago suggests that re-treatment with antivirals of persons who are re-infected with Hep C is critical to achieve the WHO incidence reduction objective by 2030.
2019 International HBV meeting “Molecular Biology of hepatitis B viruses
Melbourne, VIC, Australia
October 1-5, 2019
Masataka Tsuge, Ken Tsushima, Nobuhiko Hiraga, Takuro Uchida, Michio Imamura, C. Hayes Nelson, Harel Dahari, Susan L. Uprichard, Kazuaki Chayama. Analysis of the association between HBV infection and long term trends in intrahepatic gene expression.
Delaina May, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Harel Dahari, Kazuaki Chayama and Susan L Uprichard. HBV infection and spread in HepG2-NTCP cells initiated by low MOI inoculation in the absence of PEG.
17th International Conference of Numerical Analysis and Applied Mathematics (ICNAAM 2019)
Rhodes, Greece
September 23-28, 2019
Alexander Churkin, Vladimir Reinharz, Stephanie Lewkiewicz, Harel Dahari, Danny Barash. HCVMultiscaleFit: A Simulator for Parameter Estimation in Multiscale Models of Hepatitis C Virus Dynamics. (Oral talk)
SIAM Conference on the Life Sciences (LS18)
Minneapolis, Minnesota, USA
August 6-9, 2019
Danny Barash, Vladimir Reinharz, Alexander Churkin, Harel Dahari. Numerical Methods for Solving and Optimizing Multiscale Models of Hepatitis C Virus Dynamics (Oral talk)
Annual meeting of the Theoretical Biology and the Society for Mathematical Biology
Montreal, Canada
July 21-26, 2019
Mini-Symposia titled: “Hepatitis B viral dynamics: mathematical and numerical methods”.
Vladimir Reinharz, Danny Barash, and Harel Dahari. PDE modeling simulations and fitting methods for understanding hepatitis B virus infection in humanized mice. (Oral talk)
Preeti Dubey, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Kazuaki Chayama* Harel Dahari. Modeling hepatitis B virus infection in primary human hepatocytes. (Oral talk)
The International Liver Congress, 54th annual meeting of the European Association for the Study of the Liver
Vienna, Austria
April 10-14, 2019
Yuji Ishida, Preeti Dubey, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Harel Dahari*, Kazuaki Chayama*. Characterization of HBV kinetics during infection and treatment in primary human hepatocytes. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e701. https://doi.org/10.1016/S0618-8278(19)31399-4
Upendra Kumar, Rafaela VP Ribeiro, Susan L. Uprichard, Marcos Galasso, Atul Humar, Marcelo Cypel, Scott J. Cotler, Harel Dahari*, Jordan J. Feld*. Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e494–e495. https://doi.org/10.1016/S0618-8278(19)30971-5 (oral ePoster)
Louis Shekhtman, Scott J. Cotler, Susan L. Uprichard, Michel Bazinet, Victor Pantea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Adalbert Krawczyk, Andrew Vaillant, Harel Dahari. Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e463. https://doi.org/10.1016/S0618-8278(19)30913-2
2019 AASLD/EASL HCV Special Conference
Miami, FL, USA
February 1‐2, 2019
Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Basmattee Boodram, Jonathan Ozik, Harel Dahari. Agent-based modeling of persons who inject drugs in metropolitan Chicago suggests that re-treatment with antivirals of persons who are re-infected with Hep C is critical to achieve the WHO incidence reduction objective by 2030
69th Annual Meeting of the American Association for the study of Liver Diseases
San Francisco, CA, USA, Nov 9-13, 2018
Etzion O*, Dahari H*, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Uprichard SL, Sneh Arbib O, Munteanu D, Braun M, Cotler SJ, Abufreha N, Mor O, Shlomai A. Response-guided therapy with DAA shortens treatment duration in 50% of HCV treated patients. Hepatology 2018; 68(6); 1468A – 1469A. (Late-Breaking # 34).https://doi.org/10.1002/hep.30353
25th International Symposium on HCV and related Viruses
Dublin, Ireland
Oct 8-11, 2018
Karina Durso-Cain, Peter Kumberger, Harel Dahari, Frederik Graw, Susan L. Uprichard. Dissecting the contribution of cell-to-cell spread to HCV infection dynamics
Global Hepatitis Summit
Toronto, Canada
May 2018
Binhui Deng, Sijia Lou, Preeti Dubey, Ohad Etzion, Kazuaki Chayama, Susan L Uprichard, Mark Sulkowski, Scott J Cotler, Harel Dahari. Modeling time to cure after short-duration treatment for chronic HCV with daclatasvir, asunaprevir, beclabuvir and sofosbuvir: The FOURward Study. (Travel award) Journal Viral Hepatitis, 2018, Vol 25 Suppl S2; pg 58.
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.45_12923
VA Research Week
May 14 – 18, 2018
Sarah Rahman, Kushal Shah, Veronica Loy, Cara Joyce, Harel Dahari, Roshani Naidu, Steve Scaglione and Susan L. Uprichard. Assessing Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
The International Liver Congress, 53rd annual meeting of the European Association for the Study of the Liver
Paris, France
April 11-15, 2018
Preeti Dubey, Christopher Koh, Pallavi Surana, Susan L. Uprichard, Ma Ai Thanda Han, Nancy Fryzek, Gitanjali Subramanya, Devika Kapuria, Ohad Etzion, Varun Takyar, Yaron Rotman, Cihan Yurdaydin, Jeffrey S. Glenn, Scott J. Cotler, Theo Heller and Harel Dahari. Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV infected patients: A phase 2 LOWR HDV-3 study. Journal Hepatology 2018; Vol. 68, Suppl 1, S508
Upendra Kumar, Takuro Uchida, Atesmachew Hailegiorgis, Nobuhiko Hiraga, Kevin Walsh, Michio Imamura, Christopher Koh, Theo Heller, Jeffrey S. Glenn, Susan L. Uprichard, Kazuaki Chayama, Harel Dahari. Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling approach. Journal Hepatology 2018; Vol. 68, Suppl 1, S783
Atesmachew Hailegiorgis, Yuji Ishida, Michio Imamura, Nobuhiko Hiraga, Hiroshi Yokomichi , Chise Tateno, Susan L. Uprichard, Kazuaki Chayama ,Harel Dahari. Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach. Journal Hepatology 2018; Vol. 68, Suppl 1, S782-S783
Louis Shekhtman, Nathaniel Borochov, Scott J. Cotler, Leeor Hershkovich, Susan L. Uprichard, Mamun Al-Mahtab, Michel Bazinet, Andrew Vaillant, Harel Dahari. Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection. Journal Hepatology 2018; Vol. 68, Suppl 1, S508